Stay updated with breaking news from Affimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Affimed (NASDAQ:AFMD – Get Rating) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The […]
Several brokerages have updated their recommendations and price targets on shares of Affimed (NASDAQ: AFMD) in the last few weeks: 3/27/2023 – Affimed had its “overweight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $7.00 price target on the stock. 3/24/2023 – Affimed was downgraded by analysts at StockNews.com from […]
StockNews.com downgraded shares of Affimed (NASDAQ:AFMD – Get Rating) from a hold rating to a sell rating in a research report released on Friday morning. A number of other analysts have also issued reports on the company. Truist Financial reduced their target price on Affimed from $12.00 to $8.00 in a report on Monday, December […]
Wells Fargo & Company reissued their overweight rating on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note published on Monday morning, Benzinga reports. Wells Fargo & Company currently has a $7.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the stock. […]
StockNews.com lowered shares of Affimed (NASDAQ:AFMD – Get Rating) from a hold rating to a sell rating in a research note released on Friday morning. Several other research firms have also recently weighed in on AFMD. Stifel Nicolaus lowered their price target on Affimed from $2.00 to $1.00 and set a hold rating on the […]